By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Challenging the immunosuppressive paradigm with a novel drug for autoimmune diseases.
Artax Biopharma is a private, early-stage company in preclinical development of its lead drug to treat autoimmunity via a new pathway, Nck (non-catalytic region of tyrosine kinase adaptor protein 1). Coded AX-158, the drug is one of many molecules the company has built to inhibit Nck and thereby modulate T cell-regulated immunity without immunosuppression. AX-158 will enter clinical trials in 2021. More compounds in the AX-100, -300, and -400 series may serve as backups or additional autoimmune treatments in the future.